2014 FRAX Based Lebanese Osteoporosis Guidelines
Developed by the Lebanese National Task Force for Osteoporosis and Metabolic Bone Disorders*
Endorsed by:
Lebanese Society for Osteoporosis and Metabolic Bone Disorders, Lebanese Society of Endocrinology, Lebanese Society of Obstetrics and Gynecology, Lebanese Society of Rheumatology, Lebanese Orthopedics Society, Lebanese Society of Radiology, Lebanese Society of Family Medicine, Lebanese Society of Internal Medicine, Lebanese Society of General Practitioners.

A. Who to TEST (by BMD) to decide Who to TREAT

Patient fulfills any of the following:
* Age > 65 years
* Presence of vertebral deformity or fragility fracture
* Radiologic evidence of low bone density
* Chronic glucocorticoid therapy (> 3-6 months)
* Aromatase inhibitors or androgen deprivation therapy

Yes
No

Do BMD
Derive MOF 10-year risk using FRAX to decide on treatment ³

FRAX 6-14% ⁴
FRAX<6%
FRAX>14%

Calculate 10-year MOF ¹ risk using FRAX ²

FRAX above age-specific threshold?
Yes
No

Reassure and monitor ⁵

B. Who to TREAT

Patient fulfills any of the following:
Postmenopausal women and men (≥ 50 years) with history of fragility fracture:
1- Spine
2- Hip
3- Two or more (≥ 2) other fragility fractures

Yes
No

TREAT ⁶

Do BMD
Derive MOF 10-year risk using FRAX to decide on treatment ³

1 MOF: Major Osteoporotic fractures.
2 FRAX online link: https://www.shef.ac.uk/FRAX/tool.jsp
3 Treat if MOF 10-year risk is above age-specific threshold as outlined on verso page.
4 Within 2-4% above or below 10% threshold.
5 Periodically re-evaluate in 2-5 years, depending on the clinical context.

*Lebanese National Task Force for Osteoporosis and Metabolic Bone Disorders Members
Ghada El-Hajj Fuleihan, MD, MPH; Rafic Baddoura, MD, MPH; Marlene Chakhtoura, MD, MSc; Asma Arabi, MD, MSc; George Halaby, MD; Imad Uthman, MD; Jad Okais, MD; Ibrahim Salti, MD, PhD; Muhieddine Seoud, MD; Asaad Taha, MD; Naji Attallah, MD.
2014 FRAX Based Lebanese Osteoporosis Guidelines
Developed by the Lebanese National Task Force for Osteoporosis and Metabolic Bone Disorders*

Endorsed by:
Lebanese Society for Osteoporosis and Metabolic Bone Disorders, Lebanese Society of Endocrinology, Lebanese Society of Obstetrics and Gynecology, Lebanese Society of Rheumatology, Lebanese Orthopedics Society, Lebanese Society of Radiology, Lebanese Society of Family Medicine, Lebanese Society of Internal Medicine, Lebanese Society of General Practitioners.

WHO TO TEST

Definite indications in both men and women:
- >65 years: age as a risk factor
- Presence of vertebral deformity or fragility fracture
- Radiological evidence of low bone density
- Chronic glucocorticoid therapy (>3-6 months)
- Aromatase inhibitors or androgen deprivation therapy

All other indications in postmenopausal women and older men:
Use FRAX Risk Factors to derive fracture risk. If FRAX risk estimate based on risk factors is close to 10% (6-14%), measure BMD to further refine risk assessment

WHO TO TREAT

Patients with Fracture:
Postmenopausal women and men ≥50 years with history of fragility fracture: Spine or Hip or ≥2 other fragility fractures

OR

Patients at High Risk for Fracture:
Individuals defined by the Lebanese guidelines based on age specific FRAX threshold (graph/table)

LEBANESE FRAX INTERVENTION THRESHOLDS

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Intervention threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 70</td>
<td>10</td>
</tr>
<tr>
<td>71</td>
<td>11</td>
</tr>
<tr>
<td>72</td>
<td>12</td>
</tr>
<tr>
<td>73</td>
<td>13</td>
</tr>
<tr>
<td>74</td>
<td>14</td>
</tr>
<tr>
<td>75</td>
<td>15</td>
</tr>
<tr>
<td>76</td>
<td>16</td>
</tr>
<tr>
<td>77</td>
<td>17</td>
</tr>
<tr>
<td>78</td>
<td>19</td>
</tr>
<tr>
<td>79</td>
<td>20</td>
</tr>
<tr>
<td>80</td>
<td>21</td>
</tr>
</tbody>
</table>

PREVENTION: http://www.aub.edu.lb/FM/CMOP/Pages/LebaneseGuidelines.aspx

- Regular weight-bearing exercise
- Fall prevention
- Avoid tobacco use and excess alcohol intake
- Elemental calcium (including dietary intake) at 1,200 mg/day
- Vitamin D supplementation:
  - Desirable range 20-40 ng/ml
  - The recommended vitamin D intake, as a maintenance regimen, is:
    - Children-adolescents: 15–25 μg (600–1,000 IU) daily
    - Adults under 50 years of age: 15–25 μg (600–1,000 IU) daily
    - High-risk* and older adults: 20–50 μg (1,000–2,000 IU) daily

*High risk individuals are those with osteoporosis on pharmacologic therapy, with fractures, or conditions known to affect vitamin D metabolism or action: steroids, anticonvulsants, malabsorption, bypass surgery, cirrhosis and patients with secondary hyperparathyroidism

* Lebanese National Task Force for Osteoporosis and Metabolic Bone Disorders Members
Ghada El-Hajj Fuleihan, MD, MPH; Rafic Baddoura, MD, MPH; Marlene Chakhtoura, MD, MSc; Asma Arabi, MD, MSc; George Halaby, MD; Imad Uthman, MD; Jad Okais, MD; Ibrahim Salti, MD, PhD; Muhieddine Scoue, MD; Asaad Taha, MD; Naji Attallah, MD.
POSTMENOPAUSAL OSTEOPOROSIS (PMO)

- Alendronate, risedronate, zoledronic acid and denosumab can be considered as first-line therapy.
- Ibandronate may be considered as first-line therapy in young postmenopausal women for vertebral fracture prevention.
- For women 65 years or older with severe osteoporosis, defined as a low BMD (T-score ≤ -2.5) and a prevalent vertebral fracture, teriparatide can be considered as a first-line therapy.
- Other potential candidates for teriparatide include:
  - Postmenopausal women with very low BMD (T-score ≤ -3.5).
  - Postmenopausal women who sustain > 2 fragility fractures despite an adequate trial of bisphosphonates (1-year period).
- For postmenopausal women < 60 years with vasomotor symptoms, hormone therapy can be considered as a first-line (See table on efficacy of osteoporosis approved therapies).

OSTEOPOROSIS IN MEN

- Alendronate, risedronate, zoledronic acid and denosumab can be considered as first-line therapy.
- Teriparatide should be considered as a second-line therapy for men 65 years or older who have severe osteoporosis and prevalent fragility fractures.
- Testosterone is only indicated in men with a definite diagnosis of hypogonadism and under close expert medical supervision due to various complications.
(See table on efficacy of osteoporosis approved therapies).

AROMATASE INHIBITORS AND ANDROGEN DEPRIVATION THERAPY PATIENTS

Women on aromatase inhibitors and men on androgen deprivation therapy, bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) or Denosumab should be considered.

GLUCOCORTICIOD INDUCED OSTEOPOROSIS


* Lebanese National Task Force for Osteoporosis and Metabolic Bone Disorders Members
Ghada El-Hajj Fuleihan, MD, MPH; Rafic Baddoura, MD, MPH; Marlene Chakhtoura, MD, MSc; Asma Arabi, MD, MSc; George Halaby, MD; Imad Uthman, MD; Jad Okais, MD; Ibrahim Salti, MD, PhD; Muhieddine Seoud, MD; Asaad Taha, MD; Naji Attallah, MD.
**Efficacy of Osteoporosis Approved Medications in North America and Europe**

**By Approval Indication and by Skeletal Site**

<table>
<thead>
<tr>
<th>Medications</th>
<th>PMO</th>
<th>MO</th>
<th>GIOP</th>
<th>Fracture Risk Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-Remodeling Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alendronate</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>PMO</td>
</tr>
<tr>
<td>Ibandronate</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>PMO</td>
</tr>
<tr>
<td>Risedronate</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>PMO</td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>PMO and MO</td>
</tr>
<tr>
<td>Bazedoxifene</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>PMO</td>
</tr>
<tr>
<td>Lasofoxifene</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>PMO</td>
</tr>
<tr>
<td>Raloxifene</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>PMO</td>
</tr>
<tr>
<td>Denosumab</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>PMO and MO</td>
</tr>
<tr>
<td>Estrogen</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>PMO</td>
</tr>
<tr>
<td>Conjugated estrogen/ Bazedoxifene</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>-</td>
<td>✓</td>
<td>-</td>
<td>PMO</td>
</tr>
<tr>
<td>Tibolone</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>PMO</td>
</tr>
<tr>
<td><strong>Anabolic Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teriparatide</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>PMO and MO</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strontium ranelate</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>PMO</td>
</tr>
</tbody>
</table>

GIOP: Glucocorticoid-Induced Osteoporosis; MO: Men Osteoporosis; PMO: Postmenopausal Osteoporosis; ¹ For PMO at high risk of fracture; ² For PMO with previous fragility fracture.

*Lebanese National Task Force for Osteoporosis and Metabolic Bone Disorders Members*

Ghada El-Hajj Fuleihan, MD, MPH; Rafic Baddoura, MD, MPH; Marlene Chakhtoura, MD, MSc; Asma Arabi, MD, MSc; George Halaby, MD; Imad Uthman, MD; Jad Okais, MD; Ibrahim Salti, MD, PhD; Muhieddine Scoud, MD; Asaad Taha, MD; Naji Attallah, MD.

These printouts were made possible thanks to an educational grant from Eli Lilly and Company.